Objectives:Benign prostatic hyperplasia(BPH)is a common benign tumor in men,with an age-related prevalence of multifactorial etiology.The present study aimed to accurately assess and predict the effect of co-existing ...Objectives:Benign prostatic hyperplasia(BPH)is a common benign tumor in men,with an age-related prevalence of multifactorial etiology.The present study aimed to accurately assess and predict the effect of co-existing metabolic syndrome(MtS)upon treatment outcomes of combination medical therapy in select patients of lower urinary tract symptoms(LUTS)due to BPH.Methods:After obtaining informed consent from the patients,70 eligible patients with LUTS due to BPH with and without MtS were enrolled in this study from September 2022 to January 2024 from the outpatient clinic at the University College of Medical Sciences and Guru Teg Bahadur Hospital,Delhi and were treated with a combination of Tamsulosin and Dutasteride,for two months,as per the protocol.The outcomes measured were a change in the International Prostate Symptom Score(IPSS),mean flow rate(MFR),and peak urine flow(Qmax)rates.Data was analysed using SPSS version 23.Results:The reduction in IPSS was higher in the control group than in the case group(p<0.001),and the difference in MFR between the groups was also statistically significant(p<0.001).Although there was a significant change in Qmax in both groups,the difference in the improvement in Qmax between the two groups was not significant(p<0.829).The control group appeared to have achieved better symptomatic relief after treatment than did the case group.Conclusion:Metabolic syndrome had a negative adverse impact on medical treatment outcomes in selected patients of LUTS due to BPH.The study suggests that urologists should actively consider and appropriately counsel patients with LUTS-BPH and co-existing metabolic syndrome before selecting such patients for combination medical therapy.展开更多
Biochemical components of Moso bamboo(Phyllostachys pubescens)are critical to physiological and ecological processes and play an important role in the material and energy cycles of the ecosystem.The coupled PROSPECT w...Biochemical components of Moso bamboo(Phyllostachys pubescens)are critical to physiological and ecological processes and play an important role in the material and energy cycles of the ecosystem.The coupled PROSPECT with SAIL(PROSAIL)radiative transfer model is widely used for vegetation biochemical component content inversion.However,the presence of leaf-eating pests,such as Pantana phyllostachysae Chao(PPC),weakens the performance of the model for estimating biochemical components of Moso bamboo and thus must be considered.Therefore,this study considered pest-induced stress signals associated with Sentinel-2A/B images and field data and established multiple sets of biochemical canopy reflectance look-up tables(LUTs)based on the PROSAIL framework by setting different parameter ranges according to infestation levels.Quantitative inversions of leaf area index(LAI),leaf chlorophyll content(LCC),and leaf equivalent water thickness(LEWT)were derived.The scale conversions from LCC to canopy chlorophyll content(CCC)and LEWT to canopy equivalent water thickness(CEWT)were calculated.The results showed that LAI,CCC,and CEWT were inversely related with PPC-induced stress.When applying multiple LUTs,the p-values were<0.01;the R2 values for LAI,CCC,and CEWT were 0.71,0.68,and 0.65 with root mean square error(RMSE)(normalized RMSE,NRMSE)values of 0.38(0.16),17.56μg cm-2(0.20),and 0.02 cm(0.51),respectively.Compared to the values obtained for the traditional PROSAIL model,for October,R2 values increased by 0.05 and 0.10 and NRMSE decreased by 0.09 and 0.02 for CCC and CEWT,respectively and RMSE decreased by 0.35μg cm-2 for CCC.The feasibility of the inverse strategy for integrating pest-induced stress factors into the PROSAIL model,while establishing multiple LUTs under different pest-induced damage levels,was successfully demonstrated and can potentially enhance future vegetation parameter inversion and monitoring of bamboo forest health and ecosystems.展开更多
The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms （LUTS） in men with benign prostatic hyperplasia （BPH） from randomi...The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms （LUTS） in men with benign prostatic hyperplasia （BPH） from randomized controlled trials. We searched PubMed （1966- December 2011）, Embase （1974-December 2011） and the Cochrane Library Database （2011, Issue 12）. The assessed outcome measures were the change from baseline for the International Prostate Symptom Score （IPSS）, quality of life （QoL） score, peak urine maximum flow rate （Qmax）, QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Qmax（mean difference （MD）=-2.78, P〈O.O0001; MD=-O.42, P--O.O04; MD= 1.17, P〈O.OOOOl,respectively） and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score （IPSS： MD=- 1.14, P=O.02; QoL score： MD=-0.26, P=O.02） and inferior to the 0.2 mg tamsulosin group with respect to Qmax （MD=-0.85, P=O.01）. In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin.展开更多
这篇综述探讨了慢性全身性炎症在良性前列腺增生发病机制中的作用,良性前列腺增生是一种常见于老年男性的疾病,可导致下尿路症状(LUTS),严重影响中老年人的生活质量。虽然前列腺增生通常与衰老和激素变化有关,但越来越多的证据表明,由...这篇综述探讨了慢性全身性炎症在良性前列腺增生发病机制中的作用,良性前列腺增生是一种常见于老年男性的疾病,可导致下尿路症状(LUTS),严重影响中老年人的生活质量。虽然前列腺增生通常与衰老和激素变化有关,但越来越多的证据表明,由肥胖和代谢综合征等疾病引起的慢性全身性炎症是疾病进展的关键因素。以白细胞介素-6 (IL-6)和肿瘤坏死因子-α (TNF-α)等促炎标志物升高为特征的慢性全身性炎症,促进前列腺细胞增殖和组织重塑,导致前列腺增大。本综述强调了系统性炎症影响前列腺组织的机制,包括NF-κB和MAPK等关键信号通路的激活。我们还回顾了临床证据,表明系统性炎症标记物,如C-反应蛋白(CRP)和白细胞计数,与前列腺体积增加和前列腺增生患者更严重的LUTS之间有很强的相关性。本综述强调了,在BPH治疗中需要针对全身炎症,特别是对于患有严重炎症的代谢性疾病的患者。治疗前列腺增生的全身性炎症可能会有更好的改善及治疗效果。总之,通过抗炎药、他汀类药物和其他调节特定炎症通路的药物等疗法靶向全身炎症可能为减缓BPH进展和缓解症状提供有希望的解决方案。未来的研究应集中于完善这些治疗方法,并调查其长期疗效和安全性,特别是在炎症驱动的前列腺增生患者中。This review explores the role of chronic systemic inflammation in the pathogenesis of benign prostatic hyperplasia (BPH), a condition common in aging men that leads to lower urinary tract symptoms (LUTS). While BPH is often associated with aging and hormonal changes, increasing evidence suggests that systemic inflammation, driven by conditions like obesity and metabolic syndrome, is a key factor in disease progression. Chronic systemic inflammation, characterized by elevated pro-inflammatory markers such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), promotes prostatic cell proliferation and tissue remodeling, contributing to prostate enlargement. This review highlights the mechanisms by which systemic inflammation influences prostate tissue, including the activation of critical signaling pathways like NF-κB and MAPK. We also review clinical evidence showing a strong association between systemic inflammatory markers, such as C-reactive protein (CRP) and white blood cell count, with increased prostate volume and more severe LUTS in BPH patients. The purpose of this review is to emphasize the need to target systemic inflammation in BPH management, particularly for patients with metabolic conditions that exacerbate inflammation. Addressing this aspect of BPH could lead to more effective therapies and improved outcomes for patients. In conclusion, targeting systemic inflammation through therapies like anti-inflammatory drugs, statins, and other agents that modulate specific inflammatory pathways may offer promising solutions for slowing BPH progression and alleviating symptoms. Future research should focus on refining these treatments and investigating their long-term efficacy and safety, especially in patients with inflammation-driven BPH.展开更多
文摘Objectives:Benign prostatic hyperplasia(BPH)is a common benign tumor in men,with an age-related prevalence of multifactorial etiology.The present study aimed to accurately assess and predict the effect of co-existing metabolic syndrome(MtS)upon treatment outcomes of combination medical therapy in select patients of lower urinary tract symptoms(LUTS)due to BPH.Methods:After obtaining informed consent from the patients,70 eligible patients with LUTS due to BPH with and without MtS were enrolled in this study from September 2022 to January 2024 from the outpatient clinic at the University College of Medical Sciences and Guru Teg Bahadur Hospital,Delhi and were treated with a combination of Tamsulosin and Dutasteride,for two months,as per the protocol.The outcomes measured were a change in the International Prostate Symptom Score(IPSS),mean flow rate(MFR),and peak urine flow(Qmax)rates.Data was analysed using SPSS version 23.Results:The reduction in IPSS was higher in the control group than in the case group(p<0.001),and the difference in MFR between the groups was also statistically significant(p<0.001).Although there was a significant change in Qmax in both groups,the difference in the improvement in Qmax between the two groups was not significant(p<0.829).The control group appeared to have achieved better symptomatic relief after treatment than did the case group.Conclusion:Metabolic syndrome had a negative adverse impact on medical treatment outcomes in selected patients of LUTS due to BPH.The study suggests that urologists should actively consider and appropriately counsel patients with LUTS-BPH and co-existing metabolic syndrome before selecting such patients for combination medical therapy.
基金funded by the National Natural Science Foundation of China(42071300)the Fujian Province Natural Science(2020J01504)+4 种基金the China Postdoctoral Science Foundation(2018M630728)the Open Fund of Fujian Provincial Key Laboratory of Resources and Environment Monitoring&Sustainable Management and Utilization(ZD202102)the Program for Innovative Research Team in Science and Technology in Fujian Province University(KC190002)the Open Fund of University Key Lab of Geomatics Technology and Optimize Resources Utilization in Fujian Province(fafugeo201901)supported by the Research Project of Jinjiang Fuda Science and Education Park Development Center(2019-JJFDKY-17)。
文摘Biochemical components of Moso bamboo(Phyllostachys pubescens)are critical to physiological and ecological processes and play an important role in the material and energy cycles of the ecosystem.The coupled PROSPECT with SAIL(PROSAIL)radiative transfer model is widely used for vegetation biochemical component content inversion.However,the presence of leaf-eating pests,such as Pantana phyllostachysae Chao(PPC),weakens the performance of the model for estimating biochemical components of Moso bamboo and thus must be considered.Therefore,this study considered pest-induced stress signals associated with Sentinel-2A/B images and field data and established multiple sets of biochemical canopy reflectance look-up tables(LUTs)based on the PROSAIL framework by setting different parameter ranges according to infestation levels.Quantitative inversions of leaf area index(LAI),leaf chlorophyll content(LCC),and leaf equivalent water thickness(LEWT)were derived.The scale conversions from LCC to canopy chlorophyll content(CCC)and LEWT to canopy equivalent water thickness(CEWT)were calculated.The results showed that LAI,CCC,and CEWT were inversely related with PPC-induced stress.When applying multiple LUTs,the p-values were<0.01;the R2 values for LAI,CCC,and CEWT were 0.71,0.68,and 0.65 with root mean square error(RMSE)(normalized RMSE,NRMSE)values of 0.38(0.16),17.56μg cm-2(0.20),and 0.02 cm(0.51),respectively.Compared to the values obtained for the traditional PROSAIL model,for October,R2 values increased by 0.05 and 0.10 and NRMSE decreased by 0.09 and 0.02 for CCC and CEWT,respectively and RMSE decreased by 0.35μg cm-2 for CCC.The feasibility of the inverse strategy for integrating pest-induced stress factors into the PROSAIL model,while establishing multiple LUTs under different pest-induced damage levels,was successfully demonstrated and can potentially enhance future vegetation parameter inversion and monitoring of bamboo forest health and ecosystems.
文摘The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms （LUTS） in men with benign prostatic hyperplasia （BPH） from randomized controlled trials. We searched PubMed （1966- December 2011）, Embase （1974-December 2011） and the Cochrane Library Database （2011, Issue 12）. The assessed outcome measures were the change from baseline for the International Prostate Symptom Score （IPSS）, quality of life （QoL） score, peak urine maximum flow rate （Qmax）, QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Qmax（mean difference （MD）=-2.78, P〈O.O0001; MD=-O.42, P--O.O04; MD= 1.17, P〈O.OOOOl,respectively） and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score （IPSS： MD=- 1.14, P=O.02; QoL score： MD=-0.26, P=O.02） and inferior to the 0.2 mg tamsulosin group with respect to Qmax （MD=-0.85, P=O.01）. In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin.
文摘这篇综述探讨了慢性全身性炎症在良性前列腺增生发病机制中的作用,良性前列腺增生是一种常见于老年男性的疾病,可导致下尿路症状(LUTS),严重影响中老年人的生活质量。虽然前列腺增生通常与衰老和激素变化有关,但越来越多的证据表明,由肥胖和代谢综合征等疾病引起的慢性全身性炎症是疾病进展的关键因素。以白细胞介素-6 (IL-6)和肿瘤坏死因子-α (TNF-α)等促炎标志物升高为特征的慢性全身性炎症,促进前列腺细胞增殖和组织重塑,导致前列腺增大。本综述强调了系统性炎症影响前列腺组织的机制,包括NF-κB和MAPK等关键信号通路的激活。我们还回顾了临床证据,表明系统性炎症标记物,如C-反应蛋白(CRP)和白细胞计数,与前列腺体积增加和前列腺增生患者更严重的LUTS之间有很强的相关性。本综述强调了,在BPH治疗中需要针对全身炎症,特别是对于患有严重炎症的代谢性疾病的患者。治疗前列腺增生的全身性炎症可能会有更好的改善及治疗效果。总之,通过抗炎药、他汀类药物和其他调节特定炎症通路的药物等疗法靶向全身炎症可能为减缓BPH进展和缓解症状提供有希望的解决方案。未来的研究应集中于完善这些治疗方法,并调查其长期疗效和安全性,特别是在炎症驱动的前列腺增生患者中。This review explores the role of chronic systemic inflammation in the pathogenesis of benign prostatic hyperplasia (BPH), a condition common in aging men that leads to lower urinary tract symptoms (LUTS). While BPH is often associated with aging and hormonal changes, increasing evidence suggests that systemic inflammation, driven by conditions like obesity and metabolic syndrome, is a key factor in disease progression. Chronic systemic inflammation, characterized by elevated pro-inflammatory markers such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), promotes prostatic cell proliferation and tissue remodeling, contributing to prostate enlargement. This review highlights the mechanisms by which systemic inflammation influences prostate tissue, including the activation of critical signaling pathways like NF-κB and MAPK. We also review clinical evidence showing a strong association between systemic inflammatory markers, such as C-reactive protein (CRP) and white blood cell count, with increased prostate volume and more severe LUTS in BPH patients. The purpose of this review is to emphasize the need to target systemic inflammation in BPH management, particularly for patients with metabolic conditions that exacerbate inflammation. Addressing this aspect of BPH could lead to more effective therapies and improved outcomes for patients. In conclusion, targeting systemic inflammation through therapies like anti-inflammatory drugs, statins, and other agents that modulate specific inflammatory pathways may offer promising solutions for slowing BPH progression and alleviating symptoms. Future research should focus on refining these treatments and investigating their long-term efficacy and safety, especially in patients with inflammation-driven BPH.
